A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Status:
Recruiting
Trial end date:
2028-01-31
Target enrollment:
Participant gender:
Summary
This trial will study brentuximab vedotin to find out whether it is an effective treatment
for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study
will be older or will have other conditions that make them unable to have standard
chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with
other drugs.